Ophthalmology · Thousand Oaks, CA
NPI
1023050655
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
351 Rolling Oaks Dr Ste 102
Thousand Oaks, CA, 91361
Phone (805) 497-3744
Groups this clinician bills Medicare through
Medicare paid, 2024
$687K
17,728 services
Medicare patients, 2024
1,135
Average age 76
Drug cost, 2024
$211K
911 prescriptions
Company payments, 2025
$1,799
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Ebroon was code J0585 (injection, onabotulinumtoxina, 1 unit), 12,502 times for 51 patients. In total Daniel Ebroon billed 17,728 services in 68 codes, and Medicare paid $687K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 12,502 | 51 | $4.98 | $62K |
| 99214 Office E&M - Established | Office | 1,168 | 581 | $100.30 | $117K |
| 68840 Eye | Office | 829 | 454 | $163.87 | $136K |
| 92285 Standard X-ray | Office | 701 | 606 | $19.76 | $14K |
| 99213 Office E&M - Established | Office | 325 | 221 | $70.12 | $23K |
| 92014 Ophthalmological E&M | Office | 217 | 164 | $99.94 | $22K |
| 68761 Eye | Office | 215 | 120 | $174.56 | $38K |
| 92082 Vision, Hearing, and Speech Services | Office | 190 | 181 | $38.13 | $7,244 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 185 | 132 | $0.75 | $138 |
| 67840 Eye | Office | 172 | 140 | $219.28 | $38K |
| 11900 Skin | Office | 167 | 132 | $43.09 | $7,196 |
| 92004 Ophthalmological E&M | Office | 156 | 156 | $104.21 | $16K |
| 64612 Musculoskeletal | Office | 144 | 50 | $162.97 | $23K |
| 99204 Office E&M - New | Office | 117 | 117 | $126.23 | $15K |
| 67820 Eye | Office | 105 | 59 | $14.95 | $1,570 |
By year: 2022 $572K for 17,370 services; 2023 $668K for 18,961 services; 2024 $687K for 17,728 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Ebroon prescribed most often to Medicare patients was Tobramycin-Dexamethasone (Tobramycin/Dexamethasone), with 181 prescriptions and refills. In total Daniel Ebroon wrote 911 Medicare prescriptions that cost $211K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tobramycin-Dexamethasone Tobramycin/Dexamethasone | 181 | 203 | 147 | $7,342 |
| Doxycycline Hyclate Generic | 161 | 440 | 125 | $13K |
| Erythromycin Erythromycin Base | 134 | 146 | 118 | $1,102 |
| Restasis Cyclosporine | 83 | 139 | 28 | $80K |
| Xiidra Lifitegrast | 63 | 81 | 22 | $54K |
| Epinastine Hcl Generic | 58 | 71 | 32 | $2,869 |
| Cyclosporine Generic | 37 | 61 | 22 | $16K |
| Prednisolone Acetate Generic | 32 | 44 | 26 | $1,330 |
| Minocycline Hcl Generic | 25 | 55 | 15 | $828 |
| Miebo Perfluorohexyloctane/Pf | 22 | 27 | Under 11 | $21K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 20 | 20 | 20 | $46.41 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 19 | 19 | 16 | $167 |
| Azelastine Hcl Generic | 14 | 26 | Under 11 | $718 |
Brand drugs: 307 claims; generic drugs: 604 claims; opioid claims: 31.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Ebroon $1,799 ($1,799 in general payments such as food, travel and fees) from 11 companies. The largest payer was Tarsus Pharmaceuticals, Inc. with $374.
| Company | Payments | Amount |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. TARS | 10 | $374 |
| Amgen Inc. AMGN | 8 | $355 |
| Abbvie Inc. ABBV | 11 | $230 |
| Alcon Vision LLC ALC | 4 | $220 |
| Glaukos Corporation GKOS | 1 | $127 |
| ANI Pharmaceuticals, Inc. ANIP | 1 | $116 |
| Bausch & Lomb Americas Inc. BLCO | 5 | $110 |
| Harrow Eye, LLC | 3 | $83.92 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 3 | $78.15 |
| Dompe US, Inc. | 2 | $73.14 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.